Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Related Articles

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Haematologica. 2016 05;101(5):e196-9

Authors: Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiapella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S

PMID: 26858355 [PubMed - indexed for MEDLINE]

http://ift.tt/2E9kyQm